Nivolumab is a monoclonal antibody and a PD-1 inhibitor (programmed death receptor inhibitor) which is prescribed for cancer treatment. The therapeutic efficacy of Bacillus calmette-guerin ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

With this new treatment, scientists believe they found a way to reduce long-term side effects of therapy—including ... The FDA will determine whether nivolumab should be added as standard ...

Nivolumab was first evaluated in a phase I ... with 52% of participants achieving a complete response. No grade 3/4 side effects were observed (Westin et al, 2010). Patients with heavily ...

Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC ...

You have pembrolizumab every 6 weeks or nivolumab and ipilimumab every 4 weeks. You have it as a drip into a vein. You have treatment for up to 2 years as long as it is working and the side effects ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...